TNGX FY 2024 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TNGXTango Therapeutics, Inc.

$2B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$42M+15.2% YoY

Gross Profit

$42M100.0% margin

Operating Income

-$146M-346.1% margin

Net Income

-$130M-309.7% margin

EPS (Diluted)

$-1.19

Cash Flow

Operating Cash Flow

-$132M

Free Cash Flow

-$132M

Stock-Based Comp.

$29M

Balance Sheet

Total Assets

$316M

Total Liabilities

$117M

Stockholders' Equity

$200M

Cash & Equivalents

$70M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$42M	$37M	+15.2%
Gross Profit	$42M	$37M	+15.2%
Operating Income	-$146M	-$114M	-27.5%
Net Income	-$130M	-$102M	-28.1%